KLRB1 and neoplasm: AlloCAR-NKT cells are expected to target tumor cells through multiple surface receptors, involving CAR recognition of CAR antigen, TCR recognition of CD1d and NKR recognition of NK ligands expressed on most tumor cells (Fig. 2a)18.